Literature DB >> 33109047

Perspectives for the Use of N-acetylcysteine as a Candidate Drug to Treat COVID-19.

Pan Luo1, Yi Liu1, Dong Liu1, Juan Li1.   

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndromerelated coronavirus-2 (SARS-CoV-2), has become an ongoing pandemic worldwide. However, there are no vaccines or antiviral drugs with proven clinical efficacy. Therefore, a remedial measure is urgently needed to combat the devastating COVID-19. The pharmacological activities of Nacetylcysteine (NAC) and its potential functions in inhibiting the progression of COVID-19 make it a promising therapeutic agent for the infection. In this mini-review, we discussed the therapeutic potential of NAC in COVID-19 from the perspective of its multisite pharmacological actions. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  COVID-19; N-acetylcysteine; SARS-COV-2; inflammation; mental disorders; nitric oxide; oxidative stress; thrombosis

Year:  2021        PMID: 33109047     DOI: 10.2174/1389557520666201027160833

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  1 in total

Review 1.  N-Acetylcysteine and Other Sulfur-Donors as a Preventative and Adjunct Therapy for COVID-19.

Authors:  Heidi N du Preez; Colleen Aldous; Hendrik G Kruger; Lin Johnson
Journal:  Adv Pharmacol Pharm Sci       Date:  2022-08-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.